Market News AIOpen the app

bioAffinity Technologies, Inc.: Other Events (BIAF)

MarketRead the original at SEC EDGAR
Good for BIAF

bioAffinity reported 235 tests, up 29%, and more ordering doctors, supporting wider use. The report gives no sales or profit figures, and the test is meant to be considered with other clinical findings.

BIAF · bioAffinity Technologies, Inc.

AI read · Good for BIAF

The AI's read

More doctors ordering the test can widen its reach and build repeat use. The company also expanded its sales team and is working on possible uses in asthma and COPD. A published study reported promising results in a defined high-risk group, but the test is meant to be used with other clinical findings. Test counts do not show how much sales or profit they brought in.

Get alerts for BIAF

Follow bioAffinity Technologies, Inc. (BIAF) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for BIAF
Free on the App Store and Google Play, or on the web.